Table 2.
Type and duration of previous antiresorptive (AR) medication in the AR pretreated and inadequate AR responder subgroups
| Prior AR Therapy | AR pretreated (n = 209) | Inadequate AR responder (n = 368) | ||
|---|---|---|---|---|
| Duration, months | Duration, months | |||
| N (%) | median (Q1, Q3) | N (%) | median (Q1, Q3) | |
| Any Antiresorptive | 209 (100.0) | 10 (2, 18) | 368 (100.0) | 54 (32, 89) |
| Any Bisphosphonate | 175 (83.7) | 7 (2, 15) | 338 (91.8) | 36 (24, 59) |
| Alendronate | 120 (57.4) | 7 (1, 13) | 218 (59.2) | 26 (13, 49) |
| Risedronate | 55 (26.3) | 3 (1, 11) | 110 (29.9) | 19 (9, 26) |
| Etidronate | 25 (12.0) | 9 (1, 17) | 145 (39.4) | 35 (19, 45) |
| IV Bisphosphonates | 12 (5.7) | 9 (6, 17) | 40 (10.9) | 17 (11, 36) |
| SERM | 26 (12.4) | 7 (2, 13) | 65 (17.7) | 21 (13, 30) |
| All ET/EPT | 24 (11.5) | 28 (12, 48) | 98 (26.6) | 82 (38, 130) |
| Calcitonin | 24 (11.5) | 3 (1, 8) | 65 (17.7) | 13 (4, 36) |
| Vitamin D Metabolites | 2 (1.0) | 8 (4, 12) | 14 (3.8) | 34 (13, 55) |
ET/EPT = estrogen therapy/estrogen progestin therapy; SERM = selective estrogen receptor modulator
IV = intravenous